NRP2 and neoplasm: The tumors treated with aNRP2-28 had a significant reduction in the percentage of cells positive for Ki-67 (Figure 6D) and fewer mitotic cells (Supplemental Figure 5B), indicating that the VEGF/NRP2 function blocking antibody also limits tumor proliferation after radiotherapy.